Resolian Opens Expanded State-of-the-Art Analytical Laboratory in Fordham, Cambridgeshire, UK

ELY, UK. July 2023 - Resolian, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its 440m² analytical laboratory in Fordham, Cambridgeshire, UK.

The new lab, which the company announced plans for earlier this year, provides a 30% larger lab to help meet the rising demand for analytical and materials science work.

“We are delighted to have expanded our lab at Fordham by over 30% to meet the growing demand.” said Analytical Sciences Operations Director Ellen Stokvis. “Our new state-of-the-art purpose-built lab further strengthens our analytical and materials science capabilities. Increasing lab space from 330m² to 440m² enables more companies to be able to work with us.

“The new laboratory space has been designed to support better collaboration and improved workflow and traffic flow and alongside our Sandwich site, this investment in the analytical and materials science area of our business means we are set up and ready to support our customers demand now and in the future.”

For more information about how Resolian is continuing to evolve to offer specialized support needed across the drug development continuum worldwide, visit the company’s new website.

About Resolian:

Resolian (formerly Alliance Pharma Inc. and Drug Development Solutions Ltd.) is a leading global research laboratory that provides specialized services in GxP and nonregulated bioanalysis, drug metabolism/pharmacokinetics (DMPK), and GMP CMC analytical and materials science. 

Over 500 experts across the U.S., U.K., and Australia deliver quality results, ensuring the highest standard of regulatory compliance throughout the drug development continuum. Resolian’s dedicated laboratories are equipped with state-of-the-art technology that meet the needs of preclinical and clinical programs at any scale.